ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0745

Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System

Sebastian Bruera1, Kristen Staggers1, Maria Suarez-Almazor2 and Sandeep Agarwal1, 1Baylor College of Medicine, Houston, TX, 2MD Anderson Cancer Center, Houston, TX

Meeting: ACR Convergence 2022

Keywords: Health Services Research, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: The coronavirus disease 2019 (COVID-19) pandemic caused a widespread and emergent use of telemedicine outpatient visits to avoid patient exposure to the SARS-CoV-2 virus. Telemedicine may have the benefit of improving missed appointment by making clinic visits more accessible, especially in patients of low socioeconomic status. We completed a retrospective cohort study in patients with systemic lupus erythematosus (SLE) of low socioeconomic status managed at a county system hospital in Houston, TX.

Methods: We performed a retrospective analysis of SLE patients in the Harris Health System (HHS), a fully integrated healthcare system that provides care to residents of Harris County, Texas. This patient population has 87% of patients who are uninsured or have public insurance. We identified established patients with SLE (seen at least once by rheumatology prior to enrollment in the cohort) who were seen between September and November both in 2019 (pre-COVID-19) and 2020 (during pandemia). The primary outcome was missed clinic visit appointments. The secondary outcome was successful laboratory testing utilization, defined as complete blood count, comprehensive metabolic panel, urine studies, complements, and anti-double stranded DNA within 30 days before or after each completed visit. As patients may have had visit appointments in multiple years, we performed generalized estimate equations (GEEs) to adjust for this, along with multivariable logistic regression models to adjust for covariates (age, gender, race, ethnicity, and utilization of SLE-related prescribed drugs at the initial visit in the period).

Results: 157 patients were included. Most were female (90.4%), Hispanic (49.3%), and had a median age of 43. Our analysis included 771 in-person visits and 182 telemedicine visits. Patients who had telemedicine visits were more likely to be older and prescribed mycophenolate mofetil and glucocorticoids. The no-show rate for in-person visits in 2020 was 16.2% versus 5.5% for telemedicine (p = 0.002). After multivariable adjustment, there was a significantly decreased odds of no-shows for telemedicine versus in-person clinic appointments (Odds Ratio (OR) 0.39, 95% CI 0.20-0.77), which also persisted in a subgroup analysis of patients seen at least once in 2019 and 2020 (OR 0.31, 95 CI 0.14-0.69). We also found that telemedicine visits were associated with increased utilization of urine tests compared to in-person visits (97.3% versus 86.9%, p< 0.001). Utilization for other laboratory studies, including a composite outcome, was similar for both types of visits.

Conclusion: In conclusion, this study shows that the use of telemedicine during the initial phase of the COVID-19 pandemic was associated with a low rate of missed appointments without affecting laboratory utilization. Telemedicine may be a potential strategy to improve continuity of care amongst patients with SLE, especially those with socioeconomic and access to healthcare barriers.


Disclosures: S. Bruera, None; K. Staggers, None; M. Suarez-Almazor, Eli Lilly, Pfizer, Celgene, ChemoCentryx, Gilead; S. Agarwal, None.

To cite this abstract in AMA style:

Bruera S, Staggers K, Suarez-Almazor M, Agarwal S. Use of Telemedicine in Patients with Systemic Lupus Erythematosus in a Publicly Funded Hospital System [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/use-of-telemedicine-in-patients-with-systemic-lupus-erythematosus-in-a-publicly-funded-hospital-system/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-telemedicine-in-patients-with-systemic-lupus-erythematosus-in-a-publicly-funded-hospital-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology